Straits Times Index
3,110.73 +36.47 (+1.19%) Nikkei
32,307.86 -550.45 (-1.68%) Hang Seng
16,334.37 -11.52 (-0.07%) FTSE 100
7,554.47 +40.75 (+0.54%) Bitcoin USD
43,733.18 +291.40 (+0.67%) CMC Crypto 200
903.11 +6.40 (+0.71%)
Precision BioSciences, Inc. (DTIL)
| Previous close | 0.4050 |
| Open | 0.4045 |
| Bid | 0.3996 x 1000 |
| Ask | 0.4001 x 1100 |
| Day's range | 0.3951 - 0.4098 |
| 52-week range | 0.2750 - 1.4500 |
| Volume | |
| Avg. volume | 878,804 |
| Market cap | 48.987M |
| Beta (5Y monthly) | 1.40 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.8600 |
| Earnings date | 07 Mar 2024 - 11 Mar 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 2.63 |
Business WirePrecision BioSciences Announces Publication in Nature Metabolism Supporting ARCUS® In Vivo Gene Editing as a Potentially Curative Treatment for Mitochondrial Diseases
DURHAM, N.C., December 04, 2023--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, excision, and elimination, today announced publication in the journal Nature Metabolism of a peer reviewed manuscript titled "Efficient elimination of MELAS-associated m.3243G mutant mitochondrial DNA by an engineered mitoARCUS nuclease." This
Business WirePrecision BioSciences to Present at Hep-DART 2023
DURHAM, N.C., November 30, 2023--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, excision, and elimination, today announced that the company will present at Hep-DART 2023 in an industry session and host a poster presentation on December 5, 2023, in Los Cabos, Mexico.
Business WirePrecision BioSciences Announces Grant of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
DURHAM, N.C., November 28, 2023--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, excision, and elimination, today announced that, on November 21, 2023, the Compensation Committee of Precision’s Board of Directors approved the grant of an inducement award to a new employee under the Precision BioSciences, Inc. 2021 Employmen
